Sebastian Andersen, CEO and founder of ClarityNorth Partners, discusses H1 2026 biopharma M&A, oncology deal activity, Lilly’s strategy, capital deployment, and how transaction structure can help companies manage risk.
Sebastian Andersen
Advertisement
Sebastian Andersen is CEO and founder of ClarityNorth Partners.
Articles by Sebastian Andersen
Sebastian Andersen, CEO and founder of ClarityNorth Partners, discusses 2026 biopharma dealmaking, including M&A trends, oncology deal activity, Lilly’s acquisition strategy, and how transaction structure can help companies manage risk.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
4
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
5